Literature DB >> 16956923

Idiopathic pulmonary fibrosis: an update.

O J Dempsey1, K M Kerr, L Gomersall, H Remmen, G P Currie.   

Abstract

Idiopathic pulmonary fibrosis (IPF) is a chronic lung condition of uncertain aetiology that should be considered in the differential diagnosis of patients who experience breathlessness, cough and reduced exercise tolerance. IPF is characterized histologically by the presence of usual interstitial pneumonia, and often has typical radiological appearances. Long-term successful management options are limited and frequently unsuccessful; as the disease progresses, palliation of symptoms becomes the mainstay of treatment. In a minority of patients, lung transplantation provides the only hope of long-term survival. The median survival of patients with IPF is approximately 3 years, which in turn emphasizes the need for further investigation into its pathogenesis and potential disease-modifying pharmacological therapies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16956923     DOI: 10.1093/qjmed/hcl098

Source DB:  PubMed          Journal:  QJM        ISSN: 1460-2393


  5 in total

1.  Estimation of pulmonary vascular resistance in patients with pulmonary fibrosis by phase-contrast magnetic resonance imaging.

Authors:  Yuichiro Ayukawa; Sadayuki Murayama; Nanae Tsuchiya; Satomi Yara; Jiro Fujita
Journal:  Jpn J Radiol       Date:  2011-09-17       Impact factor: 2.374

2.  Curcumin inhibits fibrosis-related effects in IPF fibroblasts and in mice following bleomycin-induced lung injury.

Authors:  Monica R Smith; Srinivasa R Gangireddy; Venkata R Narala; Cory M Hogaboam; Theodore J Standiford; Paul J Christensen; Anand K Kondapi; Raju C Reddy
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-01-08       Impact factor: 5.464

3.  Severity classification for idiopathic pulmonary fibrosis by using fuzzy logic.

Authors:  Agnaldo José Lopes; Domenico Capone; Roberto Mogami; Regina Serrão Lanzillotti; Pedro Lopes de Melo; José Manoel Jansen
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

4.  A Phase 1b Study of Vismodegib with Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis.

Authors:  Antje Prasse; Murali Ramaswamy; Shaun Mohan; Lin Pan; Andrew Kenwright; Margaret Neighbors; Paula Belloni; Peter P LaCamera
Journal:  Pulm Ther       Date:  2019-07-19

Review 5.  The ER Stress/UPR Axis in Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis.

Authors:  Mahmoud Aghaei; Sanaz Dastghaib; Sajjad Aftabi; Mohamad-Reza Aghanoori; Javad Alizadeh; Pooneh Mokarram; Parvaneh Mehrbod; Milad Ashrafizadeh; Ali Zarrabi; Kielan Darcy McAlinden; Mathew Suji Eapen; Sukhwinder Singh Sohal; Pawan Sharma; Amir A Zeki; Saeid Ghavami
Journal:  Life (Basel)       Date:  2020-12-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.